CytoMed Therapeutics Limited Ordinary Shares
GDTCCytoMed Therapeutics Limited is a biotechnology company focused on the development of cell-based immunotherapies for cancer treatment. The company specializes in innovative therapeutic platforms aimed at enhancing immune responses against tumors, with a focus on unmet medical needs in oncology.
Company News
CytoMed Therapeutics has completed the acquisition of allogeneic gamma delta T cell technology from TC BioPharm, aiming to develop cancer treatments for China and India. The technology has completed a Phase I clinical trial and received FDA orphan drug designation for Acute Myeloid Leukemia.
The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.
Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related di...
CytoMed diversifies into regenerative medicine CytoMed diversifies into regenerative medicine
